Publications — Case studies

---

COSMODIC vs. Cancer

Device used: EX735Ag Modific

Mode of Action: S1, COSMODIC, energy — automatic mode

Total numbers of given therapies: 3 cycles (30 treatment sessions in total), each session — less than 40 minutes.

The patient was referred to my clinic with aggravating symptoms of slurred speech, swallowing difficulties and inability to close her eyelids despite partial resection of malignant thymoma to alleviate myasthenia symptoms at local hospital. Postoperatively, high dose steroid had been administered at the hospital to suppress myasthenia symptoms followed by severe side-effects such as esophageal candidiasis. And, the ophthalmologist warned that she might lose her vision sooner or later if eyelids condition did not improve.

Steroids were discontinued before the COSMODIC treatment. After 2 consecutive cycles (20 therapy sessions) of COSMODIC-therapy on face and 3 lines, she became to be able to close her eyes normally with some improvement in general condition, speech and swallowing. The only healing reaction we had experienced was temporary hyperthermia of 39 degrees Celcius after the completion of 2nd cycle.

Before treatment:

Before treatment

After treatment:

After treatment

I gave her some guidelines in diet and asked her to come back 6 months later for another cycle of COSMODIC-therapy. She revisited my clinic accordingly with better medical conditions and was given a third cycle of COSMODIC-therapy. I had advised her to keep on the diet therapy and to observe her progress together without further therapy.

And we had another treatment-free period of two and half years, observing the progress with only diet therapy.

Last month, 3 years after the first COSMODIC-therapy, she revisited my clinic with normal physical conditions and recent medical exam reports at the local hospital of complete disappearance of primary tumor and lymph node metastasis on CT scan.

COSMODIC has finally prevailed over her cancer she went back with my advice to continue to avoid any carcinogenic factor in her life.

Dr. Soo-Kyung Kim, Songpaku, Seoul, Korea